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Abstract: Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite 
continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The 
human transcriptome, which is the set of all RNA produced in a cell, is much more complex than 
previously thought and the lack of dialogue between researchers and industrials and consensus on 
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guidelines to generate data make it harder to compare and reproduce results. This European 
Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of 
transcriptomics in CVD and further the translation of experimental data into usable applications to 
improve personalized medicine in this field by creating an interdisciplinary network. It aims to 
provide opportunities for collaboration between stakeholders from complementary backgrounds, 
allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the 
cardiovascular context for translation into the clinic, thus fostering personalized medicine and 
meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular 
transcriptomics, generate innovative projects, and consolidate the leadership of European research 
groups in the field. 
COST (European Cooperation in Science and Technology) is a funding organization for research 
and innovation networks (www.cost.eu). 
Keywords: cardiovascular disease; transcriptomics; best practices and guidelines; translational 
research; personalized medicine 
 
1. Introduction 
Cardiovascular diseases (CVD) remain the main cause of death worldwide despite technological 
and medical advances and is responsible for debilitating a significant number of patients annually. 
To discover novel diagnostic and prognostic tools and develop new treatments, understanding the 
molecular mechanisms in a comprehensive view is essential. Such knowledge can forward 
personalized medicine, where interventions are tailored to the individual patient, potentially 
improving the lives of millions of people, and reducing healthcare costs. 
One way to promote this area is by studying the transcriptome, which is the set of all different 
types of RNA produced in a cell and that may be involved in the pathogenesis of several diseases, 
including cardiovascular ones. However, the human transcriptome is much more complex and 
challenging to study than previously thought, and new types of RNA are frequently revealed. 
Currently, there are relatively isolated research groups working on the same subject and sometimes 
using different standards to generate data, making it harder to compare and reproduce results. This 
is particularly true when aiming to develop products for personalized medicine because they must 
deliver accurate information and high reproducibility. 
This European Cooperation in Science and Technology (COST) Action will provide a platform 
to coordinate the efforts of different groups and offer opportunities for collaboration between 
clinicians and scientists from interdisciplinary backgrounds to more rapidly decipher the role of 
different forms of RNA in CVD and allow for the transfer of such knowledge into practical 
applications for diagnostics and therapies. CardioRNA members aim to refine and implement 
guidelines for transcriptomic studies in CVD, tackling the whole investigation pipeline to improve 
comparison between studies from different laboratories and reproducibility of results, allowing faster 
development of new RNA-based tools for personalized medicine. This Action also aims to enable 
enhancement and continuity of the network efforts in improving the understanding of the 
transcriptome in the cardiovascular context and advancement of personalized medicine. Finally, it 
has the goal to provide a platform to train the next generation of researchers and students in the field. 
2. Relevance and Timeliness 
Non-communicable diseases are the major global disease burden, with CVD as the leading cause 
of death, accounting for 17.5 million deaths per year, a number that is estimated to increase [1]. The 
socioeconomic burden of CVD due to premature deaths and reduced quality of life is substantial. It 
has been estimated to cost €210 billion annually to the European Union alone [2]. Considerable parts 
of the world are at significant risk for CVD, which, as a chronic disease, may be caused by cumulative 
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biological, behavioral, and social risks. Nonetheless, the main risk factors contributing to CVD tend 
to be consistent worldwide: Hypertension, diabetes, poor diet and obesity, physical inactivity, and 
smoking [3]. 
The modern lifestyle that promotes sedentary behavior and ingestion of high-calorie foods has 
resulted in an obesity epidemic around the globe and is related to the increasing incidence of chronic 
diseases, particularly cardiovascular ones [4]. Such aspects of modern lifestyle result in abnormal 
gene expression, contributing to the development of pathologies that significantly increase the risk 
for CVD development, such as obesity, atherosclerosis, type 2 diabetes, and hypertension. The high 
and increasing prevalence of these chronic conditions has contributed to the pandemic of CVD [5]. 
Environmental factors, such as those mentioned above, can affect gene expression, which is 
reflected by the transcriptome. For many years, there was an emphasis on the study of protein-coding 
genes giving rise to messenger RNA (mRNA). More recently, the emergence of non-coding RNA 
genes (ncRNA) has allowed the scientific community to appreciate the full complexity of the 
transcriptome. The discovery of various new classes of RNAs and their different functions has had 
profound implications for molecular biology and medical research (Figure 1). The importance of 
ncRNAs in physiological and pathological processes, such as CVD, has been frequently reinforced, 
and they have major regulatory roles in gene expression [6,7]. Thus, understanding the interactions 
between the different types of RNA, both coding and non-coding, and how they affect gene 
expression in CVD, is necessary to forward CVD management. 
 
Figure 1. Coding and non-coding RNAs in the human genome. tRNAs, transfert RNAs; rRNAs, 
ribosomal RNAs; ncRNAs, noncoding RNAs; miRNAs, microRNAs; siRNAs, small-interfering 
RNAs; snRNAs, small nuclear RNAs; snoRNAs, small nucleolar RNAs; piRNAs, piwi-interacting 
RNAs; linRNAs, long intergenic RNAs; eRNAs, extracellular RNAs; gsRNAs, germline small RNAs; 
circRNAs, circular RNAs; pRNAs, promoter-associated RNAs; mRNA, messenger RNA. 
In addition, knowledge of the transcriptome regulation and recent technological developments 
to manipulate gene expression (e.g., RNA interference, antagomiRs, gapmers, short hairpin RNA 
viral-mediated delivery of ncRNAs) allow investigation of the role and value of RNAs to personalize 
healthcare of patients affected by CVD. Thus, the transcriptome, and particularly ncRNAs, may have 
a more direct application in the clinical practice. Importantly, although most ncRNAs are found 
inside cells, they have been consistently identified in body fluids, including the blood [8]. The types 
and amounts of different ncRNAs vary and have distinct and specific profiles in different 
pathophysiological states [9,10], leading to the possibility of using these molecules as non-invasive 
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markers of disease [11,12]. Several studies have suggested that specific ncRNA profiles may be used 
as diagnostic and prognostic tools for different pathologies, including cardiovascular ones [13]. 
Early and accurate diagnosis and prognosis for CVD patients can optimize clinical decision 
making to better adjust interventions for individual patients. Currently, optimal treatment selection 
and dosage are restricted due to limited awareness of molecular and environmental information of 
patients [14]. A shift in medicine to focus on individuals rather than populations promises a more 
proactive and predictive approach [15]. This is the concept of personalized medicine, which is 
committed to inspect, diagnose, and monitor risk to ensure that patients receive treatments tailored 
to their molecular and individual configuration [14]; or, if not to the individual, treatments tailored 
to a subgroup of individuals that share similar traits and molecular outline [16]. 
However, personalized medicine presently represents a more theoretical concept than a practical 
one, with the one-size-fits-all approach being still broadly used to manage CVD. To put the promise 
of personalized medicine in practice, tools that stratify patients and improve healthcare need to be 
accessible in the clinic, making translational research essential, meaning that basic research findings 
are converted into usable applications for clinicians and patients. The basis of personalized medicine 
includes targeted therapies and biomarkers, which are molecular indicators of diagnostic and 
prognostic disease and treatment efficacy. The transcriptome provides an important source of 
therapeutic agents and biomarkers as continually demonstrated by different research [17–19]. 
Although new technologies to study the transcriptome enable information of its role in CVD 
mechanisms, much remains to be elucidated as new levels of complexity are unveiled. The slow speed 
at which advances are occurring in translational research suggests there are bottlenecks to be resolved 
[15]. Thus, there is a crucial and urgent need for a collective effort to advance in the field by 
deciphering the role of the transcriptome in CVD and create new possibilities for the development of 
innovative products for CVD management.  
3. Objectives 
This COST Action aims to accelerate the understanding of transcriptomics in CVD so 
personalized medicine advances faster in this field, addressing a current public health challenge. It 
proposes to constitute a network to offer opportunities for collaboration between clinicians, academic 
researchers from interdisciplinary backgrounds, and industry to achieve breakthroughs and allow 
the transfer of basic science into usable applications (Figure 2). CardioRNA aims to refine guidelines 
from the design to the analysis of transcriptomics data to enable better comparison between studies 
from different laboratories and reproducibility of results, facilitating the development of products. 
 
Figure 2. Different backgrounds of the network members and their interactions to impact 
cardiovascular diseases (CVD) management, thus healthcare. 
The Action will lead to creating new possibilities of basic research and product development for 
personalized medicine. CardioRNA members believe that by coordinating research activities through 
an interdisciplinary network, more meaningful results can be achieved. Furthermore, the platform 
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that will be provided by the Action will allow easier public–private partnerships to support the 
translation of the new knowledge to the clinic. 
Researchers from pertinent disciplines will connect through CardioRNA to organize activities 
to achieve the research objectives (Table 1). 
Additionally, CardioRNA will convene researchers from COST countries and International 
Partner Countries (IPC) to increase scientific dialogue and provide training in the role of 
transcriptomics in CVD through different types of meetings, involving students and early career 
investigators (ECI). It will support them to attend meetings, training schools, and short-term scientific 
meetings (STSM) within the Action. 
Table 1. Research objectives of CardioRNA. 
Specific Measurable Achievable Relevant Timely 
Further the 
understanding of the 
transcriptome’s role 
in CVD by 
establishing a 
network 
Number of 
institutions and 
investigators 
joining the 
network  
Active and 
increasing 
collaborative 
research activity in 
the field as seen in 
the biomedical 
literature 
Increased knowledge 
on the subject has 
noteworthy 
implications for the 
healthcare of 
patients with CVD 
Expansion of the 
network will be 
continuous (month 
1–48) 
Foster collaborative 
initiatives in CVD 
transcriptomics  
Number of 
Action outputs 
such as projects 
submitted for 
funding and 
scientific 
publications 
Collaborations will 
allow optimization 
and standardization 
of protocols, thus 
helping to deal 
with the 
complexity of 
studies 
Join expertise to aid 
European research 
groups  
improve and 
consolidate their 
research capacity 
and leadership in 
this field 
Project application 
to different 
funding bodies per 
year (month 12–
48) 
Develop improved 
guidelines for best 
practices and 
experimental 
standards that offer 
the greatest potential 
for cardiovascular 
transcriptomics 
studies 
Production of 
specific 
documents 
(peer-reviewed 
publications 
and others) 
Different 
guidelines and 
techniques are 
successfully used 
in this field of 
research 
Increasing 
standardization will 
facilitate comparison 
and reproducibility 
of results, allowing 
faster interpretation 
of results and 
development of new 
tools to the clinic 
Publish documents 
on (1) best 
practices on 
collection and 
processing of 
biological material 
(month 24); (2) 
experimental 
standards for RNA 
analysis in CVD 
(month 40) 
Stimulate 
development and 
optimization of 
RNA-based 
products for 
prognostic, 
diagnostic and 
therapy for CVD 
management 
Number of 
projects that 
target 
translational 
research and 
personalized 
medicine 
Partnerships from 
the network will 
facilitate study 
designs on the 
translation of 
research 
knowledge into 
medicinal products 
Regards healthcare 
improvement of 
patients with CVD 
Projects on clinical 
products 
development 
(month 48) 
4. Progress Beyond the State-of-the-Art and Innovation Potential 
The transcriptome represents all genes expressed in a tissue in a given biological state. In 
contrast to DNA sequence that is constant in an individual, there is great variation in gene expression 
in different tissues and different pathophysiological circumstances [20]. Specific signatures of the 
transcriptome have been associated with CVD phenotypes and prognosis, while the investigation of 
RNA frequently points to the structural and functional versatility of these molecules [19]. Although 
only less than 3% of the human genome represent protein-coding genes, most of the genome is 
transcribed, leading to the production of different types of RNA [21]. A more recent assessment of 
transcripts has revealed a variety of RNA types with different sizes and shapes that do not encode 
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proteins but have important regulatory functions, revealing further complexity to gene expression 
[22]. Among these ncRNAs, microRNAs are probably the most studied class. It is estimated that they 
regulate over 60% of mRNAs in humans [23] by inhibiting their translation into proteins. 
Furthermore, a single microRNA can target several mRNAs, and each mRNA can be targeted by 
multiple microRNAs [24]. They have also received much attention because, unlike most RNAs, they 
are stable in the blood and their diversity and abundance may reflect distinct health states. Such 
characteristics make these small molecules very good biomarker candidates for clinically relevant 
parameters. Besides microRNAs, there are other types of ncRNA, including circular RNAs (also 
stable in the blood) and the heterogeneous class of long non-coding RNAs (lncRNAs), playing diverse 
functions in the cell, possibly as cell-to-cell communicators and with further potential as biomarkers 
for CVD [18,25]. 
Most of the available information about the transcriptome in CVD patients comes from studies 
in non-cardiac tissues and cells, such as blood and blood cells, mainly due to their accessibility [26]. 
Nonetheless, particularly ncRNAs have been associated with nearly all cardiovascular processes, 
from normal heart development to stress response in adults, regulating heart hypertrophy, 
contractility, fibrosis, apoptosis, and gene expression. They also modulate gene expression and cell 
fate in vascular endothelial and mural (smooth muscle cells and pericytes) cells, playing a role in 
vascular biology [27,28]. Still, there is much to explore and learn about the biological mechanisms of 
ncRNAs contributing to homeostasis and CVD, a task that may be complicated partly due to their 
diverse mechanisms of action [25]. This hampers the exploitation of the full potential of RNA-based 
therapeutics. Since ncRNAs are important regulators of pathophysiological processes in the 
cardiovascular system and are present in the blood in protected forms that prevent their degradation, 
they have potential to be used as diagnostic and prognostic markers and as therapeutic targets 
[18,25,29]. 
High-throughput sequencing technologies combined with bioinformatics and computational 
biology have recently helped expand the field of transcriptomics [30]. Three main techniques are 
diffusely employed to assess RNA expression: RNA sequencing (RNA-seq), microarrays, and 
quantitative real-time polymerase chain reaction (qPCR). The first is used to obtain a complete profile 
of RNA in a sample, while the others are used to detect previously characterized RNAs [31]. All 
techniques have been widely used to enlighten our understanding of the transcriptome. However, 
the field is still in its infancy and faces many challenges. First is the complexity of the whole 
transcriptome due to its various players, their interactions, and different mechanisms of action. These 
relationships and functions are still to be determined. Another issue is the lack of consensus on all 
steps of the process on how to best perform and interpret experiments of CVD transcriptomic studies. 
Comparison of results and replication of experiments are imperative to advance in gene expression 
studies. For example, the quality of RNA is crucial to obtain reliable results [26], especially because 
RNA profiles can be easily disturbed by sample collection and processing [32]. For microRNA 
studies, in particular, different sample types (e.g., serum, plasma, blood collection in heparin) and 
measurement platforms can affect the microRNA quantification results [33]. Moreover, there is an 
urgent need to develop internal and better external reference materials for such studies. 
Thus, transcriptomics holds potential to explain fundamental biological phenomena in the 
developing field of ncRNAs within a CVD context and to advance medicine through the development 
of new diagnostic and therapeutic tools. However, for transcriptomics to fulfill the promise of 
improving healthcare, technical advances and a better understanding of the biological functions of 
ncRNA must be accomplished. This Action aims to both refine and standardize RNA analyses and 
reveal ncRNA molecules that might be useful to detect disease, predict its progression, and treat it. 
CardioRNA believes the critical challenges regarding transcriptomics studies in CVD can be 
significantly mitigated by coordinating efforts from different groups through this Action, leading to 
progress in the quality and speed of findings in the field and, hence, in healthcare. The topics to be 
tackled in this Action all contribute to such advancement, and networking will allow researchers to 
identify and come up with innovative ways to answer difficult biological questions regarding the 
role of RNA in CVD. 
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The organisation of events and meetings during this Action will pave the way for discussions 
and knowledge exchange about RNA interactions that may prevent or lead to CVD, identify gaps in 
the current transcriptomics in CVD research, and define future directions of study, all adding to the 
current state-of-the-art. The Action will support the continuity of studies and projects focusing on 
basic and translational research. By targeting best practices on every step along a transcriptomics 
CVD study pipeline, the Action aims to increase comparison and reproducibility of results between 
different laboratories that will interest investigators beyond CardioRNA members. Among the 
current partners are experts on clinical biobanking and biospecimen science who can provide a 
valuable contribution to best practices for CVD sample collection and processing and aid in the 
production of guidelines to build reference materials for CVD, for instance. Furthermore, the 
elaboration of an inventory of available patient cohorts classified by main CVD will substantially 
help researchers find adequate cohorts for their studies and may facilitate collaborations. 
The immediate benefits of this Action will be the advancement of scientific collaboration across 
Europe and the unification of transcriptomics research in CVD through the network, involving 
clinical, academic, and industrial partners. 
5. Added Value of Networking 
The potential applications of transcriptomics to aid manage CVD are clear; however, knowledge 
of its role in this context is still coming to light, especially as technologies progress and novel players 
and interactions emerge, together with new possibilities. A broader coordinated structure can 
significantly enhance existing collaborations between groups. This COST Action is well-suited for 
strengthening ongoing collaborations and establishing new ones by the creation of a large, 
interdisciplinary, and international network to jointly orchestrate and strategically plan integrated 
activities that will result in meaningful advancements in the field and, eventually, in healthcare. To 
maximize the potential of European research in the important and still developing field of 
transcriptomics and speed up breakthroughs, coordination of efforts is paramount to make a greater 
impact. 
Networking through this Action will allow, not only the initiation of important discussions 
about the transcriptome’s role in CVD, but also allow us to search, identify, and define new directions 
of study and plan future projects benefiting from the expertise of members from different disciplines. 
Also, networking is key to deal with the current lack of consensus for best practices in transcriptomics 
studies for CVD, which hinders the development of RNA-based products particularly. Appropriate 
procedures and standards throughout the entire process to generate data from RNA are key to 
determine the quality of information and its later applications. Thus, an organized network with a 
dedicated working group (WG) focusing on best practices will facilitate the establishment, 
acceptance, and dissemination of standard practices due to a large number of participants and their 
widespread locations, extending to their networks worldwide. 
6. Expected Impact 
CardioRNA expects widespread coordination of various parties interested in the context of 
transcriptomics in CVD. It anticipates exchange among the members and knowledge transfer to 
students and young researchers. Consequently, this Action will provide the basis for significant 
advancements for CVD transcriptomics and translational research as well as personalized medicine, 
impacting society in addition to the scientific community. 
In the short term, this Action will have the following scientific, technological, and socioeconomic 
impacts: 
1. Research collaboration and joint grant applications for future national and European funding;  
2. Increase the competitiveness of the network participants for European funding and the impact of resulting 
research;  
3. Encourage translational research due to the participation of industrial partners in the network;  
4. Stimulate innovative perspectives to study the transcriptome due to CardioRNA’s multidisciplinary team;  
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5. Provide opportunities and scientific training for ECI and students through workshops, training schools, 
and STSMs.  
The long-term impacts of the Action include: 
1. Expand fundamental knowledge about the role of the transcriptome in CVD to improve its prognostics, 
diagnostics, and treatment; 
2. Increase the quality of data generated and reproducibility of studies of the CVD transcriptome, thus raising 
the quality and impact of publications;  
3. Establish a leadership of both the network members and the European research axis in the proposed 
research field;  
4. Foster personalized medicine and consequently healthcare, through outcomes of public–private 
collaborations. 
7. Potential for Innovation 
The main potential innovations from this Action will be the result of increasing collaboration 
through a coordinated initiative to optimize returns on scientific investment, filling the gap of unmet 
knowledge and clinical needs in CVD personalized medicine. Thus, the Action will have two main 
potential impacts: A scientific and technological one and a socioeconomic one. From the scientific 
and technological point of view, the combination of expertise from the participating research groups 
at the front line of transcriptomics in CVD will lead to significant breakthroughs in the knowledge 
level in this field and potentially to novel intellectual property for clinical applications. This, in turn, 
will positively impact healthcare. However, to be successful in understanding transcriptomics in 
CVD and fulfilling its innovation potential as biomarkers and therapeutic targets, standardization of 
best practices is urgent. This topic will be addressed by WG2, which will devise strategies to minimize 
low reproducibility of experiments, diversity of sample types, and their collection and processing. 
Harmonization of procedures is a prerequisite to reproducibility and further industrial developments 
of translational research findings. Many new therapeutic or biomarker candidates fail to be 
reproduced/validated due to unstandardized methodologies for blood collection, marker assessment, 
or even inadequate statistical analyses. CardioRNA will provide new lines of conduct to reduce the 
rate of failure to validate new findings from research laboratories, increasing the chances of bringing 
to commercial application novel RNA targets. To minimize the risk associated with harmonization 
of procedures, the consortium gathers experts in biobanking, biospecimen science, and 
bioinformatics, fields that cover topics necessary for procedures’ standardization. Discussions and 
exchange of experiences within these experts will reduce the risk of failure to provide new 
standardization guidelines to an acceptable level. Such an endeavor can only be achieved through 
the cooperation and coordination of research groups active in the field, which this Action will 
promote. 
CardioRNA will also boost the success chances of personalized medicine endeavors, which 
require know-how from industry. The network’s industry partners are small and medium enterprise 
(SME) leaders in technology and experienced in developing biomarkers into diagnostic tools, 
discovering and designing drugs, and introducing technologies and devices into laboratories 
worldwide. Thus, this Action can also contribute to socioeconomic innovation by accelerating the 
development of products for the clinic, allowing doctors to better tailor treatment to the needs of each 
patient. For example, in some cases, a standard treatment is administered to every patient because 
there are no tools to stratify specific groups at risk, leading to increased patient burden due to 
unnecessary treatment and excessive healthcare costs. Additionally, RNA-based therapy potentially 
represents a powerful tool for personalized medicine due to their specific expression patterns 
associated with distinct pathologies. But for being in its early days, it faces challenges related to 
scientific and business aspects. CardioRNA plans to deal with these risks by building an 
interdisciplinary network to be able to have a systems approach to the complexity of the 
transcriptome and CVD and the population variability. Hence, we expect to give the CVD community 
successful case studies that can inspire and orient future efforts for therapy development. 
8. Implementation Plan 
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CardioRNA will be organized into four interrelated working groups (WG) to optimize the 
accomplishment of the main proposed goals (Figure 3). Three WGs will be dedicated to developing 
science-related activities and meet the research coordination goals. One WG will communicate within 
and outside the network and support the other WGs to develop their networking activities. 
 
Figure 3. Overall interrelations between the four CardioRNA working groups (WGs) created to 
achieve the goals described. 
8.1. WG1: Regulatory Function of the Transcriptome 
The human transcriptome is composed of coding and non-coding transcripts. Among the non-
coding transcripts, one distinguishes short ncRNAs and lncRNAs. The latter group is the largest and 
most diverse class of transcripts and exerts regulatory functions that ultimately control cell identity 
and behavior. In particular, this regulatory layer integrates developmental and environmental cues 
to shape the various cellular responses implicated in development and disease. Although microRNAs 
have been extensively studied in the context of cardiovascular disease, lncRNAs need to be 
systematically investigated. A better understanding of their importance as regulators of the gene 
programs controlling the response to stress should allow identification of new targets for improving 
diagnosis and treatment. WG1 will, therefore, focus on identifying novel ncRNAs and characterizing 
their regulatory functions in cardiovascular pathophysiology, including their interactions with 
protein-coding transcripts. One aspect that will be addressed is the difference of ncRNA expression 
according to gender. This WG will provide training in the various approaches and techniques that 
are used to probe and manipulate the transcriptome to study the role of ncRNAs in the cardiovascular 
system. 
8.2. WG2: Best Practices and Experimental Standards 
Comparison of protocols and data from different laboratories is necessary to facilitate the 
comprehension of results and advance knowledge in CVD transcriptomics. It also directly impacts 
the development of tools that can be used for diagnosis and monitoring of CVD. To compare results, 
generated data must meet common standards, which should be from the collection of samples to the 
generation and analysis of data, so that variations are minimized and results are accurate and 
reproducible. Sample collection, storage, and quality testing are critical, particularly when dealing 
with RNA due to its sensitive nature. Although guidelines exist for separate steps of sample 
collection, data generation, and analysis, a complete guideline comprising all steps that are specific 
for CVD is still lacking. WG2 will focus on the best practices for cardiovascular transcriptomic studies 
from the crucial issue of sample collection and processing, which directly impacts final results, to the 
main techniques used to study the transcriptome (qPCR, microarray, and RNA sequencing) and the 
statistical analysis. Protocols, technologies, and procedures will be assessed, and standard strategies 
will be delineated for better quality control and study comparison, tackling all the steps along the 
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process. This Action aims to bring together in WG2 experts from relevant disciplines to discuss and 
come up with guidelines to generate reference materials for CVD and also for the production of 
internal quality control materials that can be used in CVD transcriptome analyses.  
8.3. WG3: Development of Cohort Inventory 
The main goal of WG3 is to create an inventory of cohorts from healthy individuals and CVD 
patients to provide awareness of the available cohorts that can be used in research, thus, facilitating 
collaborations. Such an inventory, with key characteristics of the cohort (paying particular attention 
to gender) and information on the principal investigator, will be made available to the public through 
this COST Action’s website and possibly through websites from other relevant organizations and 
institutions (e.g., Biobanking and BioMolecular Resources Research Infrastructure Directory, 
International Society for Biological and Environmental Repositories).  
8.4. WG4: Dissemination 
WG4 will be responsible for promoting communication, knowledge exchange, and bringing new 
members to the network. This WG will organize yearly CardioRNA network meetings and provide 
support for the different WGs to organize their meetings, workshops, STSMs, and training schools. 
It will also be responsible for providing updates on the activities of the network and disseminating 
the Action’s progress and initiatives to the public. 
9. Concluding Remarks 
In summary, our COST Action aims to help alleviate the global burden of CVD by addressing 
the following challenges: Increase the knowledge of the role played by the complex transcriptome in 
CVD by coordinating efforts from different groups; refine common standards and best practices that 
will offer the greatest potential for transcriptome studies in CVD as well as increase reproducibility 
between studies and advance product development; and assure continuity of studies focusing on 
translational research and public–private partnerships to enhance personalized medicine. 
Represented by scientists with multidisciplinary backgrounds and SMEs distributed throughout 
Europe and beyond, this Action’s initiatives will potentially expand within the participants existing 
collaboration networks. Both the main subject of CardioRNA and the lack of coordination of efforts 
to deal with it are widespread, making cooperation beneficial. 
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